Psoriasis onset during infliximab treatment: Description of two cases

Rheumatology International

Volumn 26, Issue 12, 2006, Pages 1158-1160

  Volpe, Alessandro ^a   Caramaschi, Paola ^a,b   Carletto, Antonio ^a   Pieropan, Sara ^a   Bambara, Lisa Maria ^a   Biasi, Domenico ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Clinica di Medicina Interna D   (Italy)

Author keywords

Ankylosing spondylitis; Infliximab; Psoriasis; Rheumatoid arthritis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIGOXIN; HLA B27 ANTIGEN; INFLIXIMAB; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALOPECIA; ANKYLOSING SPONDYLITIS; ARTICLE; BLISTER; CASE REPORT; DERMATOMYCOSIS; DRY SKIN; FEMALE; HUMAN; HYPERHIDROSIS; HYPERKERATOSIS; HYPERPIGMENTATION; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; RHEUMATOID ARTHRITIS; ROSACEA; SEBORRHEIC DERMATITIS; SERODIAGNOSIS; TH1 CELL; TH2 CELL; URTICARIA;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SPONDYLITIS, ANKYLOSING;

EID: 33749020808     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0144-1     Document Type: Article

References (22)

1. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu R, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227-1236
2. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51:534-542
3. Langley RG, Krueger GG, Griffiths CE (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64(Suppl 2):18-23
4. Winterfield LS, Menter A, Gordon K, Gottlieb A (2005) Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 64(suppl 2):87-90
5. Keystone EC (2005) Safety of biologic therapies - an update. J Rheumatol 32(Suppl 74):8-12
6. Vegara G, Silvestre JF, Betloch I, Albares MP, Pascual JC (2002) Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 138:1258-1259
7. Mohan AK, Edwards ET, Coté TR, Siegel JN, Braun MM (2002) Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360:646
8. Tsankov N, Angelova I, Kazandjieva J (2000) Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 1:159-165
9. Grinblat B, Scheinberg M (2005) Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum 52:1333-1334
10. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ (2004) Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol 151:506-507
11. Kary S, Worm M, Fritz J, Audring H, Scherer HU, Lee HH, Staender E, Maab U, Neeck G, Renelt M, Sterry W, Burmester G (2004) New onset or aggravating of psoriatic skin lesions in patients with definitive rheumatoid arthritis under treatment with TNFα antagonists: report of 8 cases (abstract). Ann Rheum Dis 63(Suppl):277
12. Haibel H, Spiller I, Strasser C (2004) Unexpected new onset or exacerbating of psoriasis in treatment of active ankylosing spondylitis with TNFα blocking agents (abstract). Ann Rheum Dis 63(Suppl):405
13. Thurber M, Feasel A, Stroehlein J, Hymes SR (2004) Pustolar psoriasis induced by infliximab. Drugs Dermatol 3:439-440
14. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A (2005) Psoriasis induced by anti-tumor necrosis factor therapy. A paradoxical adverse reaction. Arthritis Rheum 52:2513-2518
15. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E (2004) Psoriasiform eruption induced by infliximab. Ann Pharmacother 38:54-57
16. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DL (1981) A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 30:239-245
17. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89:533-536
18. Reddy AR, Backhouse OC (2003) Does etanercept induce uveitis? Br J Ophthalmol 87:925
19. Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579-580
20. Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50:3161-3169
21. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749-760
22. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L (2001) Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 60:133-139